Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Zentalis Pharmaceuticals, Inc. (ZNTL) is a Biotechnology company based in US with a market capitalization of $290.7M. Free cash flow was negative at -$125.2M. This page tracks ZNTL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 166 employees · IPO Apr 3, 2020
Valuation
Valuation & price
$4.05as of May 17, 2026· -38.7% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.34
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$290.7M
Market cap
—
Revenue growth (YoY)
100.0%
Gross margin
-$125.2M
Free cash flow (USD)
-$206.3M
Net debt
Net cash position
1.1%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2018 → 2025
Free cash flow by year
2018 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 18, 2026Filing
Annual Meeting Results
- 8-K eventMay 27, 2026Filing
Director Appointment
- 8-K eventMay 21, 2026Filing
Clinical Trial Data Presentation
- 8-K eventMay 12, 2026Filing
Earnings Release
- Quarterly reportMay 12, 2026Filing
10-Q Filed
- 8-K eventMay 5, 2026Filing
Phase 3 Trial Initiated
- 8-K eventApr 17, 2026Filing
Data Presentation at AACR
- 8-K eventApr 9, 2026Filing
Corporate Presentation
Questions
Frequently asked questions
What is Zentalis Pharmaceuticals, Inc.'s market cap?
Zentalis Pharmaceuticals, Inc. (ZNTL) has a market capitalization of $290.7M.
What is ZNTL's P/E ratio?
A meaningful P/E ratio is not available for ZNTL — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is ZNTL's price-to-book (P/B) ratio?
ZNTL trades at 1.34 times book value per share.
Are insiders buying ZNTL stock?
SEC Form 4 filings show no open-market insider buys at Zentalis Pharmaceuticals, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.